Navigation Links
Research Institute of the MUHC awarded $1.4M grant
Date:6/9/2011

This release is available in French.

The Research Institute of the McGill University Health Centre (RI-MUHC) was one of three winners in the Fonds de la recherche en sant du Qubec (FRSQ) competition 2011-2012. The RI-MUHC won in the category of Projects for innovative strategic development aimed at supporting projects essential to maintaining the competitiveness of a research centre. This four-year grant of $1.4M will allow the RI-MUHC to lead an innovative research project to achieve their goal of developing Personalized Medicine.

"We believe that the time is ripe to undertake this innovative project with support from the FRSQ," says Dr. Vassilios Papadopoulos, Director of the RI-MUHC, the MUHC hospital-based research centre that focuses on translational research the translation of research from the bench to bedside. "If successful, this work will create the roadmap to building personalized medicine programs across a spectrum of diseases that could lead to changes in healthcare delivery."

Under the auspices of this project, an interdisciplinary research team will combine recent advances in bioinformatics, state-of-the-art technologies, and new information about how biological systems interact, to create a new RI-MUHC competitive program in translational research. Researchers will focus on Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH) leading causes of chronic liver diseases that are emerging as a potential healthcare crisis.

"NAFLD and NASH will serve as a model for this new approach to treating disease and will provide the tools to better diagnose and manage a patient's disease or predisposition to it," explains Dr. Tommy Nilsson, Director of the Proteomics and Systems Medicine Program at the RI-MUHC, Professor at McGill University, Medical Faculty, and lead investigator of the project. "This will form the basis for personalized medicine in the future."

Frequently associated with obesity, NAFLD where fat is deposited in the liver affects about one third of the adult population worldwide. In 25% of those patients, NAFLD will progress to NASH leading to inflammation and damage. Currently, there is no single reliable biochemical marker that can diagnose NAFLD or its progression to NASH and there are few treatment options other than palliative support or liver transplantation. Diagnostic markers to accurately identify patients with NAFLD and NASH are urgently needed to provide cost-effective care.

"One of the goals of our project is to identify new and valuable disease 'predictors' or biomarkers that will allow physicians to better understand and predict the progression of NAFLD and NASH," explains Dr. Nilsson who is also Director of Proteomics at The McGill University and Genome Quebec Innovation Centre. "These predictors could form the basis of new diagnostic tests or treatment options. If successful in liver disease, the methods used here could be applied to other complex diseases."

This program will provide an excellent training opportunity for a new generation of scientists and clinicians in advanced techniques in molecular and cell biology and bioinformatics.

In addition to Dr. Tommy Nilsson (RI-MUHC/McGill), Dr. Peter Metrakos (MUHC/McGill), Dr. John Bergeron (RI-MUHC/McGill), Dr. Rob Sladek (RI-MUHC/McGill), Dr. Silvia Vidal (RI-MUHC/McGill), Dr. Rima Rozen (RI-MUHC/McGill), Dr. Barry Posner (RI-MUHC/McGill), Dr. Vassilios Papadopoulos (RI-MUHC/McGill) and colleagues from MUHC and McGill participated in this research program.


'/>"/>

Contact: Julie Robert
julie.robert@muhc.mcgill.ca
514 934-1934
McGill University Health Centre
Source:Eurekalert

Related biology news :

1. Scripps Research scientists awarded $2.2 million to develop treatment for multi-drug addiction
2. Penn researchers show new evidence of genetic arms race against malaria
3. Scripps Research scientist wins $1.9 million grant to study malaria
4. Penn researchers develop biological circuit components, new microscope technique for measuring them
5. Pan-European research project for clean air
6. Researchers discover potential cause of chronic painful skin
7. Research identifies how cancer cells cheat death
8. New Interdisciplinary Scholar Networks to build better social welfare research
9. Rensselaer scholar receives NSF Research Fellowship
10. University of Iowa researchers identify caffeine-consuming bacterium
11. Emerging research in brain connectivity reveals new understanding of neurological disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... on a range of subjects including policies, debt and investment ... Speaking at a lecture to the Canadian Economics ... the country,s inflation target, which is set by both the ... "In certain areas there needs to be frequent ... not sit down and address strategy together?" He ...
(Date:6/24/2016)... Raleigh, NC (PRWEB) , ... June 24, 2016 , ... ... find the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings ... here to read it now. , Diagnostic biomarkers are signposts in the blood, ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
Breaking Biology Technology: